SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
-------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) April 11, 2000
-------------------------------
RIBOZYME PHARMACEUTICALS, INC.
- --------------------------------------------------------------------------------
(Exact name of registrant as specified in charter)
Colorado 0-27914 34-1697351
- --------------------------------------------------------------------------------
(State or other (Commission (IRS employer
jurisdiction of file number) identification no.)
incorporation
or organization)
2950 Wilderness Place, Boulder, Colorado 80301
- --------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (303) 449-6500
--------------
N/A
- --------------------------------------------------------------------------------
(Former name or former address, if changed since last report.)
5. Other Events
On April 11, 2000, Ribozyme Pharmaceuticals, Inc. (the "Company"), closed
its secondary offering of 3,150,000 shares of common stock at $18.00 per share,
for gross proceeds of $56,700,000. The offering was underwritten by ING Barings
LLC and Chase Securities, Inc. (the "Underwriters").
Also on April 11, 2000, the Underwriters gave notice to exercise their
over-allotment option to purchase 472,500 shares of common stock at $18.00 per
share. The over-allotment sale consists entirely of shares offered by selling
shareholders. The Company will not receive any of the proceeds from the sale of
these shares.
EXHIBITS
1. Press release dated April 14, 2000.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
RIBOZYME PHARMACEUTICALS, INC.
DATE: April 14, 2000 By: \s\ Lawrence E. Bullock
-------------------------------------------
Lawrence E. Bullock, Vice President of
Administration and Finance, Chief Financial
Officer and Secretary
-2-